Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer
Therapeutic resistance remains a major barrier in advanced prostate cancer (PCa), particularly after prolonged treatment with second-generation androgen receptor signaling inhibitors (ARSIs) such as enzalutamide. Tumors can evade these drugs by escaping androgen receptor (AR) dependence through cellular plasticity and lineage transitions, but alternative resistance networks remain poorly understood. Enzalutamide-resistant (ENZ-R) PCa cells showed marked activation and nuclear enrichment of the YAP-1/TAZ-TEAD complex. Disrupting this transcriptional interface with CA3 shows strong anti-metastatic effects, inhibiting migration, invasion, and colony formation across AR-dependent and AR-independent PCa cell lines, suggesting efficacy regardless of cellular lineage or AR status. Similar effects with GNE-7883, K-975, and siRNA knockdown supported a class effect. In vivo, CA3 treatment substantially reduces tumor burden in PC3 and DU145 xenograft models, supporting the systemic efficacy of disrupting the YAP-1/TAZ-TEAD axis in aggressive, AR-independent disease. Mechanistically, this anti-tumor response is driven by potent cytotoxicity: CA3 induces substantial DNA damage and apoptosis in both in vitro and in vivo settings. Moreover, we identified increased YAP-1/WWTR1(Taz) expression as a negative predictor of therapeutic response in PCa patients. These findings indicate that enzalutamide resistance creates a targetable dependence on functional Hippo transcription. Small-molecule disruption of YAP-1/TAZ-TEAD may offer a rational strategy to counter treatment resistance and lineage escape in advanced PCa.
Authors
- Guobin Kang (ORCID: https://orcid.org/0009-0009-7327-2545)
- Dorota Danuta Wyczechowska (ORCID: https://orcid.org/0000-0002-8940-6861)
- Santosh Lamichhane (ORCID: https://orcid.org/0000-0002-9292-3595)
- Hari K. Koul (ORCID: https://orcid.org/0000-0002-3747-4678)
- Vandana Mohan
- Praveen Kumar Jaiswal
- Sweaty Koul
Institutions
- Louisiana State University Health Sciences Center New Orleans (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.64898/2026.11.19.767854
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- preprint
Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Cancer Institute